B O Elektronik Yazılım Teknoloji, operating at Sakarya Teknokent in Turkey, has developed a wearable device called Signal Life, designed to support Parkinson’s patients who experience tremors. The device takes the form of an everyday bracelet based on the principle of mechanical vibrations, without requiring a Bluetooth or Wi‑Fi connection.
Development of the device took approximately two years of research and development. It uses a specific frequency that the company says sends vibrations that help alleviate some of the difficulties associated with tremors, potentially supporting the user’s ability to move more independently. The company explains that Signal Life is a support device, not a therapeutic device, and that it targets Parkinson’s patients and some other tremor conditions.
Usage and Development Specifications
The company says the bracelet is lightweight and easy to carry, and was designed with a touch interface. It takes approximately 30 minutes to charge and provides up to six hours of use. The company has also applied for a patent, although the patent procedures had not been completed when the report was published.
According to Baran Oğuz, owner of B O Elektronik Yazılım Teknoloji, 50 people were involved in the research and development phase, while more than 1,000 people began using the product over approximately six months. He added that the company recorded a positive result rate of 98% over eight weeks among Parkinson’s patients, although the report did not provide details about the study design or the measurement tools used to reach this percentage.
What Changes in Practice?
According to the uses reported in the report, the device’s practical significance lies in attempting to help patients perform daily tasks affected by tremors, such as holding a cup, eating, or writing. Users said that the device had helped them, based on their personal experiences, reduce tremors and improve movement, balance, and their ability to go out in public.
However, these accounts remain individual testimonials from users who participated in testing the device and are insufficient on their own to establish its medical effectiveness on a broad scale. The source also does not provide results from a peer-reviewed clinical trial, comparisons with other treatments and devices, or information about groups for whom use may be unsuitable. Therefore, Signal Life should be understood as a support device undergoing development and evaluation, not as a substitute for diagnosis, treatment, or medical follow-up.
Technical Context
Sakarya Teknokent operates within the central campus of Sakarya University and includes 335 offices, 133 companies, and approximately 1,450 employees. According to the report, 1,231 projects have been carried out there to date, with companies’ activities in the healthcare sector accounting for 9%. This places Signal Life among local efforts to develop wearable medical technologies, while questions regarding clinical and regulatory validation and long-term outcomes remain open.